GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and biosimilars,today announced the company has reached an exclusivecommercialization and license agreement with IntasPharmaceuticals for BAT2506, a golimum...
DetailsBAT1706 is Bio-Thera Solutions’ second EMAapproved product BAT1706 is Bio-Thera Solutions’ secondproduct receiving marketing authorization from NMPA, FDA and EMA Guangzhou, China– July 30, 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developinga p...
Guangzhou, China– July 25, 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announced thatdosing has recently begun in an integrated Phase I / Phase III clinical studyfor BAT3306, a propo...
The U.S. Food and Drug Administration (FDA)has accepted Bio-Thera’s Biologics License Applications (BLA) for BAT2206 as aninterchangeable biosimilar to reference product Stelara ® The European Medicines Agency (EMA) hasaccepted the Marketing Authorization Application (MAA) for BAT2206 as abiosimi...
